摘要
系统探讨α-2b干扰素在呼吸道感染儿对阳性的柯萨奇B组病毒抗原(CVB-Ag)的消除效应。CVB-Ag阳性呼吸道感染病儿38例,其中上呼吸道感染16例,下呼吸道感染22例,年龄2~10岁,平均4.55+3.81岁,男21例,女17例。分A(18例),B(20例)2组。CVB-Ag和CVB-IgM测定采用ELISA法。α-2b干扰素,皮下或肌肉注射5~7天,每天100万U。连续3周观测2组CVB-Ag阳性率变化,并分析CVB性心肌炎发生率。结果显示:(1)用α-2b干扰素后1~2周抗原阳性率明显降低(P<0.05)。(2)用α-2b干扰素后CVB性心肌炎发病率明显降低(P<0.01)。(3)α-2b干扰素不良反应轻。提示α-2b干扰素有快速消除CVB抗原的功效,并对降低CVB性心肌炎的发病有益。
To
study systemically the therapeutical efficacy of interferon α-2b in cosackievirus B(CVB) in
children with respiratory infection, 38 with cosackievirus B antigen (CVB-Ag) positive respiratory
tract infection cases were divided into two groups: Group A(18 cases), routine treatment and
Group B(20 cases), routine treatment plus interferon α-2b. CVB-Ag and CVB-IgM were tested by
ELISA method. Interferon α-2b was injected, subcutaneously or intramuscularly for 5~7 days,
1 million U a day. The results showed that (1) the CVB-Ag positive rate was significantly
decreased one or two weeks after using interferon α-2b;(2) there was lower incidence of CVB
myocarditis in interferon α-2b group; (3) the adverse reaction was mild. Conclusions: Interferon
α-2b was demonstrated rapid eliminating effect of CVB-Ag and provided the benefit of lowering
the incidence of CVB myocarditis.
出处
《心肺血管病杂志》
CAS
1999年第1期18-20,共3页
Journal of Cardiovascular and Pulmonary Diseases